Allschwil, Switzerland – January 30, 2026 — Idorsia Ltd. announced it will present long-term lucerastat clinical data and kidney biopsy results at the 22nd Annual WORLDSymposium™, highlighting up to 42 months of continuous treatment and, in some patients, over six years of exposure. The presentations draw from the Phase III MODIFY study and its open-label extension, offering new insights into renal outcomes, biomarker durability, and disease-modifying potential in Fabry disease, a rare, progressive lysosomal storage disorder.
Science Significance
The data to be shared reinforce lucerastat’s mechanism as an oral substrate reduction therapy (SRT) designed to reduce the synthesis of glycosphingolipids, including Gb3, which accumulate due to deficient α-galactosidase A activity in Fabry disease. Importantly, the long-term analyses indicate sustained reductions in plasma and urinary Gb3, coupled with signals of renal stabilization. Interim findings from the open-label extension show a slower rate of eGFR decline, particularly among patients with impaired baseline kidney function or rapidly deteriorating renal trajectories, suggesting a potential disease-modifying effect rather than symptomatic control alone. The kidney biopsy sub-study adds translational depth by directly assessing Gb3 accumulation across key renal cell types, strengthening the biological plausibility of observed clinical trends.
Regulatory Significance
From a regulatory standpoint, the presentation underscores Idorsia’s ongoing refinement of the optimal approval pathway for lucerastat. While the pivotal Phase III study did not meet its primary neuropathic pain endpoint, regulators increasingly value organ-protective outcomes, biomarker durability, and long-term safety, especially in rare diseases with high unmet need. The integration of biopsy-based evidence, longitudinal renal function data, and extended safety exposure aligns with evolving expectations for holistic benefit-risk assessments. These datasets may support labeling discussions centered on renal preservation and broad genotype applicability, differentiating lucerastat from mutation-specific or intravenously administered therapies.
Advertisement
Business Significance
Strategically, lucerastat represents a first-in-class, oral alternative within the Fabry treatment landscape, which is currently dominated by enzyme replacement therapies (ERTs) and select oral chaperones. Long-term durability data are critical for payer acceptance, physician confidence, and market access, particularly as healthcare systems scrutinize cost-effectiveness and treatment burden. Demonstrating sustained renal benefit over multiple years could materially enhance lucerastat’s commercial positioning and partnering value, while supporting life-cycle management opportunities across earlier disease stages and diverse patient populations.
Patients’ Significance
For patients, the implications are substantial. Fabry disease is frequently underdiagnosed, progresses insidiously, and leads to irreversible kidney, cardiac, and neurologic damage. Current therapies can be burdensome, require lifelong infusions, and may be limited by immunogenicity or mutation dependence. Lucerastat’s profile as a well-tolerated, oral therapy with evidence of renal stabilization offers hope for simpler, more accessible long-term disease management. The inclusion of female patients and those with advanced renal involvement in long-term analyses is particularly meaningful, reflecting real-world disease heterogeneity and reinforcing the therapy’s potential broad applicability.
Policy Significance
At a policy level, the data contribute to broader discussions around rare disease innovation, value-based assessment, and access equity. As newborn screening and high-risk population studies reveal higher-than-expected Fabry prevalence, healthcare systems face mounting pressure to adopt scalable, sustainable therapies. Oral disease-modifying treatments could reduce hospital resource utilization, improve adherence, and align with policy objectives to shift care from infusion centers to community-based settings. Additionally, robust long-term evidence supports evidence-informed reimbursement decisions, a growing priority for regulators and payers worldwide.
Overall, Idorsia’s WORLDSymposium presentations position lucerastat as a compelling next-generation Fabry therapy candidate, supported by extended clinical exposure, renal biomarker durability, and biopsy-level mechanistic data. As the company advances regulatory planning, these findings may help redefine expectations for oral substrate reduction therapies in rare metabolic diseases, with meaningful implications for clinical practice, health policy, and patient quality of life.
Source: Idorsia Ltd. press release
